Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro

Basit Öğe Kaydı
dc.authoridCemil Bilir / 0000-0002-1372-4791
dc.authorscopusidCemil Bilir / 23666163400
dc.authorwosidCemil Bilir / DTZ-3231-2022
dc.contributor.authorGüney Eskiler, Gamze
dc.contributor.authorDeveci Özkan, Asuman
dc.contributor.authorHacıefendi, Ayten
dc.contributor.authorBilir, Cemil
dc.date.accessioned2021-10-25T11:42:19Z
dc.date.available2021-10-25T11:42:19Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractThe therapeutic effects of abemaciclib (ABE), an inhibitor of cyclin- dependent kinases (CDK) 4/6, on the proliferation of two types of prostate cancer (PC) cells were revealed. In this study, in vitro cytotoxic and apoptotic effects of ABE on metastatic castration-resistant prostate cancer (mCRPC) androgen receptor (AR) negative PC-3 and AR mutant LNCaP PC cells were analyzed with WST-1, Annexin V, cell cycle, reactive oxygen species (ROS), mitochondrial membrane potential, RT-PCR, western blot, and apoptosis protein array. ABE considerably inhibited the growth of PC cells in a dose-dependent manner (p<0.01) and caused significant apoptotic cell death through the suppression of CDK4/6-Cyclin D complex, ROS generation and depolarization of mitochondria membrane potential. However, PC-3 cells were more sensitive to ABE than LNCaP cells. Furthermore, the expression levels of several pro-apoptotic and cell cycle regulatory proteins were upregulated by ABE in especially PC-3 cells with the downregulation of apoptotic inhibitor proteins. Our results suggest that ABE inhibits PC cell growth and promotes apoptosis and thus ABE treatment may be a promising treatment strategy in especially mCRPC. Further preclinical and clinical studies should be performed to clarify the clinical use of ABE for the treatment of PC.en_US
dc.identifier.citationGuney Eskiler, G., Deveci Ozkan, A., Haciefendi, A., & Bilir, C. (2021). Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro. Translational oncology, 15(1), 101243. Advance online publication.en_US
dc.identifier.doi10.1016/j.tranon.2021.101243en_US
dc.identifier.issue1en_US
dc.identifier.pmid34649150en_US
dc.identifier.scopus2-s2.0-85116878207en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1016/j.tranon.2021.101243
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2167
dc.identifier.volume15en_US
dc.identifier.wosWOS:000729953600004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorBilir, Cemil
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofTranslational Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAbemacicliben_US
dc.subjectApoptosisen_US
dc.subjectCDK4/6en_US
dc.subjectProstate Canceren_US
dc.titleMechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitroen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
4.pdf
Boyut:
9.34 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu